2024
Costs of care during chimeric antigen receptor T-cell therapy in relapsed/refractory B cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed/refractory B cell lymphomas. JNCI Cancer Spectrum 2024, pkae059. PMID: 39115391, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront cost
2023
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan F, Dholaria B, Maakaron J, Sandoval-Sus J, Mishra R, Saha A, Annunzio K, Bhaskar S, Sumransub N, Fijalka A, Ivanov S, Lin Y, Kharfan-Dabaja M. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation 2023, 59: 211-216. PMID: 37973893, DOI: 10.1038/s41409-023-02148-4.Peer-Reviewed Original ResearchCAR-T therapyChimeric antigen receptor T-cell therapyT-cell therapyR LBCLT therapyMedian numberResponse rateCAR-T infusionEfficacy of CD19Limited clinical activityComplete response rateCAR-T productsDuration of responseOverall response rateMulti-center studyReal-world studyMedian followR diseaseMedian durationSystemic therapyMedian timeLoncastuximab tesirineAxicabtagene ciloleucelCD19-CARClinical activityPrediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype
Verma A, Liburd S, Tobias Z, Isufi I, Pober J, Xu M. Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype. Blood 2023, 142: 2075. DOI: 10.1182/blood-2023-184963.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPre-treatment biopsiesVenular endothelial cellsLarge B-cell lymphomaMemory T cellsHigh endothelial venulesT cellsB-cell lymphomaVCAM-1E-selectinICAM-1Endothelial cellsChimeric antigen receptor T-cell therapyL-selectinPre-treatment tumor biopsiesEffector memory T cellsCentral memory T cellsCAR T-cell therapyCell therapyHEV endothelial cellsInflamed lymph nodesT-cell infiltratesT cell exhaustionT-cell therapyT-cell homing